[Familial LCAT deficiency].

Area of Science:

• Biochemistry
• Genetics
• Internal Medicine

Background:

• Familial lecithin-cholesterol acyltransferase (LCAT) deficiency, described in 1967, is a serum enzyme crucial for reverse cholesterol transport.
• LCAT deficiency leads to altered free and esterified cholesterol levels, disrupting lipoprotein structure and function.
• This condition impacts multiple organs, including kidneys, cornea, and erythrocytes, manifesting as proteinuria, renal insufficiency, corneal opacities, and hemolytic anemia.

Purpose of the Study:

• To summarize the clinical and genetic aspects of familial lecithin-cholesterol acyltransferase (LCAT) deficiency.
• To highlight the variability in clinical manifestations despite absent or low LCAT activity.

Main Methods:

• Review of existing literature on familial LCAT deficiency.
• Analysis of genetic localization and mutations within the LCAT gene.
• Correlation of biochemical findings with clinical phenotypes.

Main Results:

• LCAT deficiency is an autosomal recessive disorder caused by mutations in the LCAT gene (chromosome 16q21-22).
• Patients exhibit increased free cholesterol, decreased esterified cholesterol, and structural lipoprotein abnormalities.
• Clinical presentations are diverse, including renal, ocular, and hematologic abnormalities.

Conclusions:

• Familial LCAT deficiency results in significant lipid metabolism disturbances and multi-organ pathology.
• The variable expressivity of the disease suggests modulation by environmental factors and modifier genes.
• Further research into these modulators is warranted to understand the full spectrum of LCAT deficiency.